Literature DB >> 23428049

Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study.

Phumla Z Sinxadi1, Joel A Dave, David C Samuels, Jeannine M Heckmann, Gary Maartens, Naomi S Levitt, C William Wester, David W Haas, Todd Hulgan.   

Abstract

Studies suggest that mitochondrial DNA (mtDNA) haplogroups are associated with antiretroviral therapy (ART)-related metabolic complications and distal sensory polyneuropathy (DSP), but there have been few studies in persons of African descent. We explored such associations in South African adults. Clinical and laboratory data and DNA specimens from a cross-sectional study were used. Sequencing and Phylotree determined African mtDNA subhaplogroups. Wilcoxon and regression analyses determined associations between mtDNA subhaplogroups and ART-related complications. The 171 participants represented six major haplogroups: L0 (n=78), L1 (n=3), L2 (n=30), L3 (n=53), L4 (n=1), and L5 (n=6). Analyses were restricted to 161 participants representing L0, L2, and L3: 78% were female; the median age was 36 years. All had been exposed to thymidine analogues, 42% were on lopinavir/ritonavir (lopinavir/r), and 58% were on either efavirenz or nevirapine. Median (IQR) ART duration was 22 (14-36) months. Median fasting triglycerides were 1.60 (1.13-1.75) and 1.04 (0.83-1.45) mmol/liter among L3e1 (n=22) and other subhaplogroups, respectively (p=0.003). Subhaplogroup L3e1 [adjusted OR (aOR) 3.16 (95% CI: 1.11-8.96); p=0.03] and exposure to lopinavir/r [aOR 2.98 (95% CI: 1.02-8.96); p=0.05] were independently associated with hypertriglyceridemia, after adjusting for age, sex, and ART duration. There were no significant associations between mtDNA haplogroups and cholesterol, dysglycemia, hyperlactatemia, or lipoatrophy, or DSP. Subhaplogroup L3e1 and lopinavir/r exposure were independently associated with hypertriglyceridemia in black South Africans on ART. This is the first report to link an African mtDNA variant with hypertriglyceridemia. If replicated, these findings may provide new insights into host factors affecting metabolic complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428049      PMCID: PMC3685683          DOI: 10.1089/aid.2012.0373

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  A brief overview of mechanisms of mitochondrial toxicity from NRTIs.

Authors:  James J Kohler; William Lewis
Journal:  Environ Mol Mutagen       Date:  2007 Apr-May       Impact factor: 3.216

3.  Comprehensive association testing of common mitochondrial DNA variation in metabolic disease.

Authors:  Richa Saxena; Paul I W de Bakker; Karyn Singer; Vamsi Mootha; Noel Burtt; Joel N Hirschhorn; Daniel Gaudet; Bo Isomaa; Mark J Daly; Leif Groop; Kristin G Ardlie; David Altshuler
Journal:  Am J Hum Genet       Date:  2006-05-24       Impact factor: 11.025

4.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

5.  Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes.

Authors:  Say Viengchareun; Martine Caron; Martine Auclair; Min Ji Kim; Paule Frachon; Jacqueline Capeau; Marc Lombès; Anne Lombès
Journal:  Antivir Ther       Date:  2007

6.  Whole-mtDNA genome sequence analysis of ancient African lineages.

Authors:  Mary Katherine Gonder; Holly M Mortensen; Floyd A Reed; Alexandra de Sousa; Sarah A Tishkoff
Journal:  Mol Biol Evol       Date:  2006-12-28       Impact factor: 16.240

Review 7.  Mitochondrial function in normal and diabetic beta-cells.

Authors:  P Maechler; C B Wollheim
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

8.  Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study.

Authors:  Joanna Poulton; Jian'an Luan; Vincent Macaulay; Susie Hennings; Jo Mitchell; Nicholas J Wareham
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

9.  Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.

Authors:  L Hocqueloux; C Alberti; J-P Feugeas; M Lafaurie; E Lukasiewicz; G Bagnard; O Carel; D Erlich; J-M Molina
Journal:  HIV Med       Date:  2003-01       Impact factor: 3.180

10.  The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy.

Authors:  J A Canter; D W Haas; A R Kallianpur; M D Ritchie; G K Robbins; R W Shafer; D B Clifford; D G Murdock; T Hulgan
Journal:  Pharmacogenomics J       Date:  2007-08-07       Impact factor: 3.550

View more
  9 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 2.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

3.  An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network.

Authors:  Henry C Liu; Neema Jamshidi; Yuchen Chen; Satish A Eraly; Sai Yee Cho; Vibha Bhatnagar; Wei Wu; Kevin T Bush; Ruben Abagyan; Bernhard O Palsson; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2016-07-20       Impact factor: 5.157

Review 4.  The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy.

Authors:  Anna B Hart; David C Samuels; Todd Hulgan
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

Review 5.  Genetics of HIV-associated sensory neuropathy and related pain in Africans.

Authors:  Huguette Gaelle Ngassa Mbenda; Antonia Wadley; Zane Lombard; Catherine Cherry; Patricia Price; Peter Kamerman
Journal:  J Neurovirol       Date:  2017-05-30       Impact factor: 2.643

Review 6.  HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Authors:  Julia L Finkelstein; Pooja Gala; Rosemary Rochford; Marshall J Glesby; Saurabh Mehta
Journal:  J Int AIDS Soc       Date:  2015-01-15       Impact factor: 5.396

7.  High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals.

Authors:  M Li; Y Foli; Z Liu; G Wang; Y Hu; Q Lu; S Selvaraj; W Lam; E Paintsil
Journal:  HIV Med       Date:  2016-06-22       Impact factor: 3.180

8.  Investigating the relationship between mitochondrial genetic variation and cardiovascular-related traits to develop a framework for mitochondrial phenome-wide association studies.

Authors:  Sabrina L Mitchell; Jacob B Hall; Robert J Goodloe; Jonathan Boston; Eric Farber-Eger; Sarah A Pendergrass; William S Bush; Dana C Crawford
Journal:  BioData Min       Date:  2014-04-15       Impact factor: 2.522

9.  Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy.

Authors:  Marvin Blessings Moketla; Antonia L Wadley; Peter Kamerman; Debra de Assis Rosa
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.